Hunterase, developed by GC Pharma, is speeding up its efforts to target global markets. It is successful as a treatment for rare diseases developed in Korea, generating more than three times more sales than domestic demand in overseas markets.

According to GC Pharma on the 4th, Hunterase's sales rose 77.7% year-on-year to 23.1 billion won in the third quarter. It more than doubled from 11 billion won in the previous quarter. In the third quarter of this year, cumulative sales jumped 63.9% year-on-year to 47.2 billion won. Sales exceeded 46.2 billion won recorded over the past year.

Hunterase, which was approved in Korea in 2012, is the world's second treatment for Hunter syndrome. Hunter syn